Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Biotechnology

Healthcare
$1.69 -0.90%

-$0.01 today

Market cap
$116.77M
Beta
1.49
P/E (TTM)
-8.9
EPS (TTM)
-$0.12
52W Low $1.03High $2.98

Volume 11.56M

Average 2.73M

INO Common Stock Repurchased

Cash spent buying back the company's own shares.

Inovio Pharmaceuticals, Inc.NASDAQ: INO

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased outflow grows to $0

Q1 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How INO compares with its peers on the latest reported figures

  • INO's LTM Mar 2026 common stock repurchased of $0 is the 4th largest of the 10 companies compared; the peer median is $0.
INO Competitors Peer median
Common Stock Repurchased for INO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SEERSeer, Inc.LTM Mar 2026$12.15M -2.8%+698.9%80.8%
IRDOpus Genetics, Inc.LTM Mar 2026$509K +597.3%—4.2%
AGENAgenus Inc.LTM Mar 2026$92K +318.2%-71.6%0.1%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 ———
ALECAlector, Inc.LTM Mar 2026$0 ——0.0%
FATEFate Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 +100.0%——
ACTUActuate Therapeutics IncLTM Mar 2026$0 ———
Peer median (excluding INO) $0+209.1%+313.7%0.0%

Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Depreciation & Amortization4.73M5.5M3.5M3.13M2.99M
Deferred Income Tax04.03M(32.05K)00
Stock-Based Compensation26.34M22.56M11.07M6.6M3.76M
Change in Working Capital50.35M19.83M(10.26M)(2.66M)(9.22M)
Accounts Receivables11.03M(3.71M)9.33M1.21M0
Inventory00000
Accounts Payables26.14M32.61M(45.99M)(3.37M)(6.42M)
Other Working Capital13.18M(9.07M)26.4M(504.04K)(2.8M)
Other Non-Cash Items6.53M11.69M6.47M(3.88M)(1.21M)
Operating Cash Flow(215.71M)(216.22M)(124.37M)(104.08M)(88.63M)
Capital Expenditures(1.23M)(969.15K)(320.9K)(487.83K)(285.7K)
Acquisitions (Net)0(2M)6.22M00
Purchases of Investments(348.95M)(248.53M)(203.48M)(54.14M)(4.95M)
Sales of Investments174.84M361.08M284.93M158.64M19.27M
Other Investing Activities00059.32K0
Investing Cash Flow(175.34M)109.59M87.36M104.07M14.04M
Debt Repayment000(16.42M)0
Common Stock Issued209.44M82.96M5.46M68.31M53.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.06M(1.11M)(466.65K)(420.8K)(110.78K)
Financing Cash Flow211.5M81.84M5M51.48M53.05M
Effect of Forex Changes(30.13K)(25.56K)(3.92K)32.4K0
Net Change in Cash(179.58M)(24.81M)(32.02M)51.5M(21.54M)
Free Cash Flow(216.94M)(217.18M)(124.69M)(104.56M)(88.92M)

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.